HARROW, INC. recently released its 10-Q report, detailing its activities in the eyecare pharmaceutical industry. The company offers a wide range of ophthalmic pharmaceutical products, including ImprimisRx, IHEEZO, IOPIDINE, VEVYE, ZERVIATE, MAXITROL eye drops, ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, FLAREX, TRIESENCE, NATACYN, TOBRADEX ST, VERKAZIA, NEVANAC, and FRESHKOTE preservative free (PF) lubricant eye drops. The company was previously known as Harrow Health, Inc. and was founded in 1998, with its headquarters in Nashville, Tennessee.
In the 10-Q report, HARROW, INC. discussed various developments and financial results. Notably, the company entered into a Credit Agreement with Fifth Third Bank, National Association, providing for a senior secured revolving credit facility in the initial principal amount of $40,000,000, with an uncommitted incremental revolving line of credit in the principal amount of up to $20,000,000. Additionally, the company announced Harrow Access For All (HAFA) to expand its proprietary patient access model and entered into an Agreement and Plan of Merger to acquire the remaining equity interests of Melt Pharmaceuticals, Inc. The company also closed a private offering of $250,000,000 in 8.625% senior notes due 2030, using the proceeds to prepay all outstanding senior debt borrowings.
Furthermore, HARROW, INC. entered into a development and commercialization agreement with Samsung Bioepis Co., Ltd. for the commercialization of BYOOVIZ and OPUVIZ in the U.S. market, acquired the exclusive U.S. commercial rights to BYQLOVI from Formosa Pharmaceuticals, and announced VEVYE Access for All, a patient access program aimed at increasing patient access to VEVYE at an affordable cost. The company also initiated Project Beagle, a review of opportunities to offer ImprimisRx customers a Harrow-owned FDA-approved product alternative to a compounded formulation.
The 10-Q report also provided insights into the company's financial performance, including its revenues, which include sales of proprietary compounded formulations and branded products. The period-to-period comparisons of financial results for the three and nine months ended September 30, 2025, and 2024 were discussed, providing an overview of the company's financial performance.
Today the company's shares have moved 10.28% to a price of $37.65. For the full picture, make sure to review HARROW, INC.'s 10-Q report.
